Thursday, March 12, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Research publication trends during COVID-19

At first, COVID-19 papers (and preprints) focused on the spread of disease, the outcomes for people hospitalized, and diagnostics and testing, according to an analysis of the topics of PubMed-indexed articles by Primer, a company in San Francisco, California, that develops artificial-intelligence (AI) technologies. But these kinds of paper mostly plateaued after May, and there has been growing interest in mental-health research.

The pandemic also saw a sharp rise in sharing through preprints (articles posted online before peer review), advanced the output of male authors over female authors and affected review times — speeding them up in some topics but slowing them down in others.

More than 30,000 of the COVID-19 articles published in 2020 were preprints — between 17% and 30% of total COVID-19 research papers (depending on database searched). And, according to Dimensions, one-tenth of all preprints this year were about COVID-19.

More than half of the preprints appeared on one of three sites — medRxiv, SSRN and Research Square.

 

Source: Nature

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!